European Leukemia Trial Registry
Trial: AML MTC-Imatinib

More Details
Scientific Title Open-label Multicenter Trial of Glivec® (imatinib mesylate, formerly known as STI571) in Combination with Chemotherapy (MTC) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML)
Short Title AML MTC-Imatinib
Trialgroup NN
Type of Trial multicentric
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age -
Status Closed
Start of Recruitment 01.09.2004
Leader Bergmann, Prof. Dr. med., Lothar
Contactperson

General Contact Person
Bergmann, Prof. Dr. med., Lothar
Tel: +49 (0)69 6301 5121
Fax: +49 (0)69 6301 3876
Email: L.bergmann@em.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 04.07.2006 Anja Hellenbrecht
changed 13.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org